PerkinElmer’s Columbus data-management system and IDBS’ ActivityBase XE software will be combined.

PerkinElmer entered a collaboration with IDBS that will focus on improving data analysis and interpretation of high-content screening (HCS). The companies will integrate PerkinElmer’s Columbus™ image data-management system with IDBS’ ActivityBase XE screening data-management software.

A unified interface is planned that will allow access to Columbus’ image data-storage capabilities and ActivityBase XE’s screening data-analysis and interpretation features. “The future of high-content screening lies in an increased synergy between technologies that integrate vast image content with large compound sets, to generate actionable research data,” says Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer.

“We feel this collaboration with IDBS is a timely and highly promising advance in giving researchers access to greater insights into the cell-based mechanisms of disease as well as development of novel therapies based on greater understanding of the origins of diseases.”

PerkinElmer’s Columbus software is a solution for high-volume image storage and management. Designed as a partner product for the Opera™ system, PerkinElmer’s confocal microplate imaging reader, the software has the added benefit of full compatibility with a wide range of image file formats. The Columbus software can be used to archive and manage images from confocal and standard research microscopes and acts as a central repository for all image data.

IDBS’ ActivityBase XE delivers ultrahigh-performance data analysis, data visualization/interpretation, and storage in one working environment. The new features in ActivityBase XE enable users to analyze rich, multivariant data, perform curve fitting and complex statistics within each well of a MTS, HTS, or uHTS experiment. The software enables domain-aware interpretation through intuitive visualization, featuring a wide selection of data views not available in generic spreadsheet packages or nonspecialist solutions.

Previous articleInvestigators Find New Syndrome Linked to Congenital Neutropenia
Next articleBioDelivery Sciences Grants Meda Full Rights to Cancer Pain Drug for $3M